



FLINT

401 S. Ballenger Hwy.
Flint, Mi 48532

September 4, 2014

U.S. Nuclear Regulatory Commission
Region III
Materials Licensing Section
2443 Warrenville Road
Lisle, Illinois 60532-4351

Dear Sir/Madam:

We wish to amend our Materials License #21-04171-04, McLaren Flint to add authorization rights for Kiran Devisetty, M.D. to perform the following:

- 1) 35.300 - Oral administration of I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries).
- 2) 35.300 - Oral administration of I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries).
- 3) 35.300 - Parenteral administration of any beta-emitter or photon-emitting radionuclide with photon energy less than 150 keV requires a written directive.

Enclosed is NRC Form 313A for Kiran Devisetty, M.D. along with a copy of his board certification.

If you have any questions, please contact Arthur Ewald at (810) 342-3805.

Sincerely,

Christopher J. Conlin, M.D.
Radiation Safety Officer

Brent Wheeler
VP Ancillary/Support Service

RECEIVED SEP 16 2014

**AUTHORIZED USER TRAINING AND EXPERIENCE
AND PRECEPTOR ATTESTATION**
(for uses defined under 35.300)
[10 CFR 35.390, 35.392, 35.394, and 35.396]

APPROVED BY OMB: NO. 3150-0120
EXPIRES: (05/31/2015)

Name of Proposed Authorized User

KIRAN DEVISSETTY, M.D.

State or Territory Where Licensed

MICHIGAN

Requested Authorization(s) (check all that apply):

35.300 Use of unsealed byproduct material for which a written directive is required

OR

35.300 Oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)

35.300 Oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)

35.300 Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

35.300 Parenteral administration of any other radionuclide for which a written directive is required

PART I -- TRAINING AND EXPERIENCE
(Select one of the three methods below)

* Training and Experience, including board certification, must have been obtained within the 7 years preceding the date of application or the individual must have related continuing education and experience since the required training and experience was completed. Provide dates, duration, and description of continuing education and experience related to the uses checked above.

1. Board Certification

a. Provide a copy of the board certification.

b. For 35.390, provide documentation on supervised clinical case experience. The table in section 3.c. may be used to document this experience.

c. For 35.396, provide documentation on classroom and laboratory training, supervised work experience, and supervised clinical case experience. The tables in sections 3.a., 3.b., and 3.c. may be used to document this experience.

d. Skip to and complete Part II Preceptor Attestation.

2. Current 35.300, 35.400, or 35.600 Authorized User Seeking Additional Authorization

a. Authorized User on Materials License _____ under the requirements below or equivalent Agreement State requirements (check all that apply):

35.390 35.392 35.394 35.490 35.690

b. If currently authorized for a subset of clinical uses under 35.300, provide documentation on additional required supervised case experience. The table in section 3.c. may be used to document this experience. Also provide completed Part II Preceptor Attestation.

c. If currently authorized under 35.490 or 35.690 and requesting authorization for 35.396, provide documentation on classroom and laboratory training, supervised work experience, and supervised clinical case experience. The tables in sections 3.a., 3.b., and 3.c. may be used to document this experience. Also provide completed Part II Preceptor Attestation.

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

3. **Training and Experience for Proposed Authorized User**

a. Classroom and Laboratory Training 35.390 35.392 35.394 35.396

| Description of Training | Location of Training | Clock Hours | Dates of Training* |
|--|-----------------------|-------------|--------------------|
| Radiation physics and instrumentation | UNIVERSITY of Chicago | 16 | 2005-2009 |
| Radiation protection | UNIVERSITY of Chicago | 16 | 2005-2009 |
| Mathematics pertaining to the use and measurement of radioactivity | UNIVERSITY of Chicago | 16 | 2005-2009 |
| Chemistry of byproduct material for medical use | UNIVERSITY of Chicago | 16 | 2005-2009 |
| Radiation biology | UNIVERSITY of Chicago | 16 | 2005-2009 |
| Total Hours of Training: | | 80 | |

b. Supervised Work Experience 35.390 35.392 35.394 35.396

If more than one supervising individual is necessary to document supervised training, provide multiple copies of this page.

| Supervised Work Experience | | Total Hours of Experience: 10 | |
|--|---|--|----------------------|
| Description of Experience Must Include: | Location of Experience/License or Permit Number of Facility | Confirm | Dates of Experience* |
| Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys | McLAREN FLINT Hospital | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 2012-2014 |
| Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters | McLAREN FLINT Hospital | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 2012-2014 |
| Calculating, measuring, and safely preparing patient or human research subject dosages | McLAREN FLINT Hospital | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 2012-2014 |
| Using administrative controls to prevent a medical event involving the use of unsealed byproduct material | McLAREN FLINT Hospital | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 2012-2014 |
| Using procedures to contain spilled byproduct material safely and using proper decontamination procedures | McLAREN FLINT Hospital | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | 2012-2014 |

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

3. Training and Experience for Proposed Authorized User (continued)

b. Supervised Work Experience (continued)

| | |
|--|--|
| Supervising Individual HESHAM E. GAYAR, M.D. | License/Permit Number listing supervising individual as an authorized user 21-04171-04 |
|--|--|

Supervising individual meets the requirements below, or equivalent Agreement State requirements (check all that apply)**:

- 35.390 With experience administering dosages of:
- 35.392 Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)
- 35.394 Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)
- 35.396 Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required
- Parenteral administration of any other radionuclide requiring a written directive

** Supervising Authorized User must have experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status.

c. Supervised Clinical Case Experience

If more than one supervising individual is necessary to document supervised work experience, provide multiple copies of this page.

| Description of Experience | Number of Cases Involving Personal Participation | Location of Experience/License or Permit Number of Facility | Dates of Experience* |
|---|--|---|--|
| Oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries) | 3 | McLAREN FLINT Hospital LICENSE # 21-04171-04 | 7/18/2014 7/29/2014 8/15/2014 |
| Oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries) | 3 | McLAREN FLINT Hospital LICENSE # 21-04171-04 | 7/24/2014 8/8/2014 8/22/2014 |
| Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required | 3 | McLAREN FLINT Hospital LICENSE # 21-04171-04 | 2/17/2014 3/7/2014 8/4/2014 |
| Parenteral administration of any other radionuclide for which a written directive is required <div style="border: 1px solid black; width: 150px; height: 30px; margin: 5px auto;"></div> (List radionuclides) | | | |

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

3. Training and Experience for Proposed Authorized User (continued)

c. Supervised Clinical Case Experience (continued)

| | |
|--|--|
| Supervising Individual HESHAM E. GAYAR, M.D. | License/Permit Number listing supervising individual as an authorized user 21-04171-04 |
|--|--|

Supervising individual meets the requirements below, or equivalent Agreement State requirements (check all that apply)**:

- 35.390 With experience administering dosages of:
- 35.392 Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)
- 35.394 Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)
- 35.396 Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required
- Parenteral administration of any other radionuclide requiring a written directive

** Supervising Authorized User must have experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status.

d. Provide completed Part II Preceptor Attestation.

PART II – PRECEPTOR ATTESTATION

Note: This part must be completed by the individual's preceptor. The preceptor does not have to be the supervising individual as long as the preceptor provides, directs, or verifies training and experience required. If more than one preceptor is necessary to document experience, obtain a separate preceptor statement from each.

By checking the boxes below, the preceptor is attesting that the individual has knowledge to fulfill the duties of the position sought and not attesting to the individual's "general clinical competency."

First Section

Check one of the following for each requested authorization:

For 35.390:

Board Certification

I attest that KIRAN DEVISETTY, M.D. has satisfactorily completed the training and experience requirements in 35.390(a)(1).
Name of Proposed Authorized User

OR

Training and Experience

I attest that _____ has satisfactorily completed the 700 hours of training and experience, including a minimum of 200 hours of classroom and laboratory training, as required by 10 CFR 35.390 (b)(1).
Name of Proposed Authorized User

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

Preceptor Attestation (continued)

First Section (continued)

For 35.392 (Identical Attestation Statement Regardless of Training and Experience Pathway):

I attest that KIRAN DEVISSETTY, M.D. has satisfactorily completed the 80 hours of classroom
Name of Proposed Authorized User
and laboratory training, as required by 10 CFR 35.392(c)(1), and the supervised work and clinical case
experience required in 35.392(c)(2).

For 35.394 (Identical Attestation Statement Regardless of Training and Experience Pathway):

I attest that KIRAN DEVISSETTY, M.D. has satisfactorily completed the 80 hours of classroom
Name of Proposed Authorized User
and laboratory training, as required by 10 CFR 35.394 (c)(1), and the supervised work and clinical case
experience required in 35.394(c)(2).

Second Section

I attest that KIRAN DEVISSETTY, M.D. has satisfactorily completed the required clinical case
Name of Proposed Authorized User

experience required in 35.390(b)(1)(ii)G listed below:

- Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)
- Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)
- Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required
- Parenteral administration of any other radionuclide requiring a written directive

Third Section

I attest that KIRAN DEVISSETTY, M.D. has satisfactorily achieved a level of competency to
Name of Proposed Authorized User

function independently as an authorized user for:

- Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)
- Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)
- Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required
- Parenteral administration of any other radionuclide requiring a written directive

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

Fourth Section

For 35.396:

Current 35.490 or 35.690 authorized user:

I attest that _____ is an authorized user under 10 CFR 35.490 or 35.690
Name of Proposed Authorized User

or equivalent Agreement State requirements, has satisfactorily completed the 80 hours of classroom and laboratory training, as required by 10 CFR 35.396 (d)(1), and the supervised work and clinical case experience required by 35.396(d)(2), and has achieved a level of competency sufficient to function independently as an authorized user for:

- Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required
- Parenteral administration of any other radionuclide for which a written directive is required

OR

Board Certification:

I attest that KIRAN DEVISSETTY, M.D. has satisfactorily completed the board certification
Name of Proposed Authorized User

requirements of 35.396(c), has satisfactorily completed the 80 hours of classroom and laboratory training required by 10 CFR 35.396 (d)(1) and the supervised work and clinical case experience required by 35.396(d)(2), and has achieved a level of competency sufficient to function independently as an authorized user for:

- Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required
- Parenteral administration of any other radionuclide for which a written directive is required

Fifth Section


Complete the following for preceptor attestation and signature:

I meet the requirements below, or equivalent Agreement State requirements, as an authorized user for:

- 35.390 35.392 35.394 35.396

I have experience administering dosages in the following categories for which the proposed Authorized User is requesting authorization.

- Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)
- Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)
- Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required
- Parenteral administration of any other radionuclide requiring a written directive

| | | | |
|---|---|---|-----------------------|
| Name of Preceptor <u>HESHAM E. GAYAR, M.D.</u> | Signature  | Telephone Number <u>810-392-3800</u> | Date <u>9-4-14</u> |
|---|---|---|-----------------------|

License/Permit Number/Facility Name
21-04171-04 / McLaren Flint Hospital

The American Board of Radiology

*Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Radiation Oncology, the Association of
University Radiologists, and the American Association of Physicists in Medicine
Hereby certifies that*

Kiran Bevisetty, MD

*Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications, including
passing the examinations conducted under the authority of
The American Board of Radiology,
demonstrating to the satisfaction of the Board that he is qualified to practice,
and is therefore awarded the Board's certification in the specialty of*

AB Eligible


Radiation Oncology

Effective June 30, 2010

Sam J. Harty
President

Richard T. Morin
Secretary-Treasurer

Harvey S. Goldstein
Executive Director



Certificate No. 59861

Valid through 2020




FLINT

*C. Conlin, m.d.
Radiation Safety Officer*

401 South Ballenger Highway
Flint, Michigan 48532-3638

U.S. Nuclear Regulatory Commission
Region III
Materials Licensing Section
2443 Warrenville Road
Lisle, Illinois 60532-4351

604 605 60532S N2-66



4124140910-114706

2

60532

RECEIVED SEP 16 2014

